Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.82 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.82 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.82 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.82 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.82 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.82 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.82 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 10/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10258182 | 1.00 | MAP2K1 (0.82) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL12869782 | 1.00 | MAP2K1 (0.82) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL18088594 | 0.92 | MAP2K1 (0.84) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL19050685 | 0.92 | MAP2K1 (0.72) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL20385641 | 0.92 | MAP2K1 (0.69) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL19050686 | 0.91 | MAP2K1 (0.69) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL10314890 | 0.90 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL346872 | 0.90 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL345334 | 0.90 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL29360059 | 0.90 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701360-B2 | Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition | Genuv Inc. (KR) | 2023-07-18 | — | — | US | disclosed |
| US-20210401844-A1 | Composition for Inducing Differentiation and Protection of Neural Stem Cells and Method for Inducing Neuro-Regeneration Using the Same Composition | Genuv Inc. (KR) | 2021-12-30 | — | — | US | disclosed |
| US-11147816-B2 | Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition | Genuv Inc. (KR) | 2021-10-19 | — | — | US | disclosed |
| US-20200046706-A1 | Composition for Inducing Differentiation and Protection of Neural Stem Cells and Method for Inducing Neuro-Regeneration Using the Same Composition | Genuv Inc. (KR) | 2020-02-13 | — | — | US | disclosed |
| US-10485802-B2 | Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition | Genuv Inc. (KR) | 2019-11-26 | — | — | US | disclosed |
| US-20180169102-A1 | Composition for Inducing Differentiation and Protection of Neural Stem Cells and Method for Inducing Neuro-Regeneration Using the Same Composition | Genuv Inc. (KR) | 2018-06-21 | — | — | US | disclosed |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| WO-2017033113-A1 | THERAPEUTIC COMBINATIONS OF A MEK INHIBITOR AND A BTK INHIBITOR | ACERTA PHARMA B.V. (NL) | 2017-03-02 | — | — | WO | disclosed |
| US-8808742-B2 | Compositions and methods for preparing and using same | ARDEA BIOSCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110033539-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | ARDEA BIOSCIENCES, INC (US) | 2011-02-10 | — | — | US | disclosed |
| US-7759518-B2 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ARDEA BIOSCIENCES (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200046706-A1 | Composition for Inducing Differentiation and Protection of Neural Stem Cells and Method for Inducing Neuro-Regeneration Using the Same Composition | NOTCH2, APP, NOTCH1 | MAP2K1 17/4885MAP2K2 14/4885CHEK1 207/4885 |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | MAP2K1 52/4885MAP2K2 48/4885CHEK1 260/4885 |
| US-20180169102-A1 | Composition for Inducing Differentiation and Protection of Neural Stem Cells and Method for Inducing Neuro-Regeneration Using the Same Composition | NOTCH2, APP, NOTCH1 | MAP2K1 17/4885MAP2K2 14/4885CHEK1 207/4885 |
| US-11701360-B2 | Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition | NOTCH2, NOTCH1, APP | MAP2K1 17/4885MAP2K2 14/4885CHEK1 235/4885 |
| US-10485802-B2 | Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition | NOTCH2, APP, NOTCH1 | MAP2K1 17/4885MAP2K2 14/4885CHEK1 207/4885 |
| US-11147816-B2 | Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition | NOTCH2, APP, NOTCH1 | MAP2K1 17/4885MAP2K2 14/4885CHEK1 207/4885 |
| US-20210401844-A1 | Composition for Inducing Differentiation and Protection of Neural Stem Cells and Method for Inducing Neuro-Regeneration Using the Same Composition | NOTCH2, NOTCH1, APP | MAP2K1 17/4885MAP2K2 14/4885CHEK1 235/4885 |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | BRAF, MAPK1, MAP2K2 | MAP2K1 7/4885MAP2K2 3/4885CHEK1 507/4885 |
| US-20110033539-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | HMGCR, PCSK9, C5 | MAP2K1 4649/4885MAP2K2 4647/4885CHEK1 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.